A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma
Latest Information Update: 09 Dec 2024
At a glance
- Drugs Erdafitinib (Primary)
- Indications Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
Most Recent Events
- 13 Aug 2024 Results published in the BMC Cancer
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 13 Nov 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.